«Much to our surprise, the trial showed that patients receiving standard therapy compared to those receiving cetuximab
with standard therapy had no difference in outcomes,» said study author Dr. Steven Alberts, a professor
of oncology
at the Mayo Clinic College
of Medicine in Rochester, Minn. «It also indicates that
disease in earlier
stages may be
different than
diseases in later
stages.»